688520 神州细胞
交易中 09-10 10:57:25
资讯
新帖
简况
每周股票复盘：神州细胞（688520）股东户数下降12.74%
证券之星 · 08-30
每周股票复盘：神州细胞（688520）股东户数下降12.74%
神州细胞（688520）2025年中报简析：净利润同比下降126.87%，三费占比上升明显
证券之星 · 08-29
神州细胞（688520）2025年中报简析：净利润同比下降126.87%，三费占比上升明显
神州细胞(688520.SH)发布半年度业绩，归母净亏损3377万元，同比由盈转亏
智通财经 · 08-28
神州细胞(688520.SH)发布半年度业绩，归母净亏损3377万元，同比由盈转亏
图解神州细胞中报：第二季度单季净利润同比下降289.37%
证券之星 · 08-28
图解神州细胞中报：第二季度单季净利润同比下降289.37%
神州细胞(688520)6月30日股东户数0.98万户，较上期减少12.74%
证券之星 · 08-28
神州细胞(688520)6月30日股东户数0.98万户，较上期减少12.74%
8月14日神州细胞涨5.21%，申万菱信中证500指数优选增强A基金重仓该股
证券之星 · 08-14
8月14日神州细胞涨5.21%，申万菱信中证500指数优选增强A基金重仓该股
药代和患者涉嫌骗保 神州细胞称公司未被调查
中国经营网 · 08-08
药代和患者涉嫌骗保 神州细胞称公司未被调查
生物制品公司财务总监PK：百万年薪以上占比41% 神州细胞马洁年薪143万行业第三
新浪证券 · 08-08
生物制品公司财务总监PK：百万年薪以上占比41% 神州细胞马洁年薪143万行业第三
生物制品公司财务总监PK：50岁以上CFO占比为38% 智翔金泰刘力文为业内最年轻CFO
新浪证券 · 08-08
生物制品公司财务总监PK：50岁以上CFO占比为38% 智翔金泰刘力文为业内最年轻CFO
神州细胞今日主力净流出1.2亿 短期波动后看业绩兑现
智选洞察 · 08-07
神州细胞今日主力净流出1.2亿 短期波动后看业绩兑现
生物类似药集采启动，国内企业将迎接“价格战”
健识局 · 08-04
生物类似药集采启动，国内企业将迎接“价格战”
新冠药物概念盘中跳水，尖峰集团跌0.49%
市场透视 · 08-04
新冠药物概念盘中跳水，尖峰集团跌0.49%
生物制品行业点评报告-减重赛道全球前沿进展跟踪(一)：AMYLIN布局正当时
开源证券 · 08-03
生物制品行业点评报告-减重赛道全球前沿进展跟踪(一)：AMYLIN布局正当时
华创医药投资观点&研究专题周周谈·第137期：CXO行业：新周期、新起点
华创证券 · 08-01
华创医药投资观点&研究专题周周谈·第137期：CXO行业：新周期、新起点
神州细胞股价下跌5.01% 因资金博弈加剧股价震荡
智选洞察 · 08-01
神州细胞股价下跌5.01% 因资金博弈加剧股价震荡
神州细胞收盘下跌3.53%，滚动市盈率328.47倍，总市值333.47亿元
金融界 · 07-30
神州细胞收盘下跌3.53%，滚动市盈率328.47倍，总市值333.47亿元
单抗概念盘中拉升，苑东生物涨7.44%
市场透视 · 07-29
单抗概念盘中拉升，苑东生物涨7.44%
华创医药投资观点&研究专题周周谈·第136期：高血压创新药是一笔好生意吗？
华创证券 · 07-25
华创医药投资观点&研究专题周周谈·第136期：高血压创新药是一笔好生意吗？
生物制品行业盘中拉升，科兴制药涨8.38%
市场透视 · 07-17
生物制品行业盘中拉升，科兴制药涨8.38%
神州细胞涨5.05% 政策利好与机构资金流入推动股价上行
智选洞察 · 07-17
神州细胞涨5.05% 政策利好与机构资金流入推动股价上行
加载更多
公司概况
公司名称：
北京神州细胞生物技术集团股份公司
所属行业：
医药制造业
上市日期：
2020-06-22
主营业务：
北京神州细胞生物技术集团股份公司的主营业务是恶性肿瘤、自身免疫性疾病、感染性疾病和遗传病等多个治疗和预防领域的生物药产品研发和产业化。公司的主要产品是SCT800（安佳因）、SCT400（安平希）、SCT630（安佳润）、SCT510（安贝珠）、SCT-I10A（安佑平）、SCT1000SCT650C、SCTC21C、SCTB35、SCTB14、SCTB41、SCTV02、SCTV04C、SCT520FF、SCTT11、SCTB39-1、SCTB39G、SCT640C。
发行价格：
25.64
{"stockData":{"symbol":"688520","market":"SH","secType":"STK","nameCN":"神州细胞","latestPrice":58.92,"timestamp":1757473044000,"preClose":60.88,"halted":0,"volume":3012392,"delay":0,"changeRate":-0.0322,"floatShares":445000000,"shares":445000000,"eps":-0.1068,"marketStatus":"交易中","change":-1.96,"latestTime":"09-10 10:57:24","open":60.88,"high":62.27,"low":58.9,"amount":182000000,"amplitude":0.0554,"askPrice":59.01,"askSize":0,"bidPrice":58.92,"bidSize":2,"shortable":0,"etf":0,"ttmEps":-0.1068,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1757475000000},"marketStatusCode":2,"adr":0,"adjPreClose":60.88,"symbolType":"stock_kcb","openAndCloseTimeList":[[1757467800000,1757475000000],[1757480400000,1757487600000]],"highLimit":66.97,"lowLimit":54.79,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":445335714,"isCdr":false,"pbRate":-53.84,"roa":"--","roe":"--","epsLYR":0.24,"committee":-0.302752,"marketValue":26239000000,"turnoverRate":0.0068,"status":1,"floatMarketCap":26239000000},"requestUrl":"/m/hq/s/688520","defaultTab":"news","newsList":[{"id":"2563640882","title":"每周股票复盘：神州细胞（688520）股东户数下降12.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563640882","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563640882?lang=zh_cn&edition=full","pubTime":"2025-08-31 03:37","pubTimestamp":1756582631,"startTime":"0","endTime":"0","summary":"截至2025年8月29日收盘，神州细胞报收于63.5元，较上周的68.06元下跌6.7%。本周，神州细胞8月25日盘中最高价报70.5元。股本股东变化股东户数变动截至2025年6月30日，神州细胞股东户数为9754.0户，较3月31日减少1424.0户，减幅12.74%。神州细胞2025年半年度报告摘要神州细胞2025年半年度报告摘要显示，公司总资产3,526,218,500.07元，较上年度末增长7.38%；归属于上市公司股东的净资产110,838,929.67元，较上年度末下降21.33%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025083100000447.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688520"],"gpt_icon":0},{"id":"2563007068","title":"神州细胞（688520）2025年中报简析：净利润同比下降126.87%，三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2563007068","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563007068?lang=zh_cn&edition=full","pubTime":"2025-08-30 06:18","pubTimestamp":1756505902,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期神州细胞发布2025年中报。截至本报告期末，公司营业总收入9.72亿元，同比下降25.5%，归母净利润-3377.11万元，同比下降126.87%。本报告期神州细胞三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达68.51%。去年的净利率为4.47%，算上全部成本后，公司产品或服务的附加值不高。持有神州细胞最多的基金为申万菱信中证500指数优选增强A，目前规模为23.63亿元，最新净值2.1204，较上一交易日上涨0.32%，近一年上涨51.36%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025083000010673.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520"],"gpt_icon":0},{"id":"2562038902","title":"神州细胞(688520.SH)发布半年度业绩，归母净亏损3377万元，同比由盈转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2562038902","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562038902?lang=zh_cn&edition=full","pubTime":"2025-08-28 18:17","pubTimestamp":1756376231,"startTime":"0","endTime":"0","summary":"智通财经APP讯，神州细胞(688520.SH)披露2025年半年度报告，报告期公司实现营收9.72亿元，同比下降25.50%;归母净利润亏损3377万元，同比由盈转亏;扣非净利润亏损3611万元，同比由盈转亏;基本每股收益-0.10元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1337394.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"神州细胞(688520.SH)发布半年度业绩，归母净亏损3377万元，同比由盈转亏","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688520"],"gpt_icon":0},{"id":"2562038899","title":"图解神州细胞中报：第二季度单季净利润同比下降289.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562038899","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562038899?lang=zh_cn&edition=full","pubTime":"2025-08-28 18:11","pubTimestamp":1756375870,"startTime":"0","endTime":"0","summary":"证券之星消息，神州细胞2025年中报显示，公司主营收入9.72亿元，同比下降25.5%；归母净利润-3377.11万元，同比下降126.87%；扣非净利润-3610.82万元，同比下降110.61%；其中2025年第二季度，公司单季度主营收入4.52亿元，同比下降34.66%；单季度归母净利润-9753.89万元，同比下降289.37%；单季度扣非净利润-5968.56万元，同比下降132.57%；负债率97.03%，投资收益36.6万元，财务费用4337.55万元，毛利率94.79%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082800035165.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520"],"gpt_icon":0},{"id":"2562082594","title":"神州细胞(688520)6月30日股东户数0.98万户，较上期减少12.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562082594","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562082594?lang=zh_cn&edition=full","pubTime":"2025-08-28 17:28","pubTimestamp":1756373305,"startTime":"0","endTime":"0","summary":"证券之星消息，近日神州细胞披露，截至2025年6月30日公司股东户数为9754.0户，较3月31日减少1424.0户，减幅为12.74%。在生物制品行业个股中，神州细胞股东户数低于行业平均水平，截至6月30日，生物制品行业平均股东户数为3.42万户。从股价来看，2025年3月31日至2025年6月30日，神州细胞区间涨幅为46.91%，在此期间股东户数减少1424.0户，减幅为12.74%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082800033216.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688520","BK0239"],"gpt_icon":0},{"id":"2559302169","title":"8月14日神州细胞涨5.21%，申万菱信中证500指数优选增强A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2559302169","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559302169?lang=zh_cn&edition=full","pubTime":"2025-08-14 16:16","pubTimestamp":1755159360,"startTime":"0","endTime":"0","summary":"证券之星消息，8月14日神州细胞涨5.21%，收盘报68.45元，换手率3.89%，成交量17.34万手，成交额11.98亿元。根据2025基金半年报公募基金重仓股数据，重仓该股的公募基金共15家，其中持有数量最多的公募基金为申万菱信基金的申万菱信中证500指数优选增强A。申万菱信中证500指数优选增强A目前规模为23.63亿元，最新净值1.9682，较上一交易日上涨1.47%，近一年上涨35.84%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081400029873.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["399006","000688.SH","000300.SH","399905","159967","000905.SH","512510","000001.SH","510300","688520","399001","159982","510880","515890","512880","BK0239"],"gpt_icon":0},{"id":"2558157289","title":"药代和患者涉嫌骗保 神州细胞称公司未被调查","url":"https://stock-news.laohu8.com/highlight/detail?id=2558157289","media":"中国经营网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558157289?lang=zh_cn&edition=full","pubTime":"2025-08-09 03:49","pubTimestamp":1754682540,"startTime":"0","endTime":"0","summary":"安佳因是神州细胞于2021年7月获批上市销售的血友病药品。据统计，上市销售4年，安佳因累计销售额已突破50亿元，并使长期亏损的神州细胞在2024年扭亏为盈。据了解，截至今年8月，全国多名神州细胞医药代表、患者卷入涉嫌骗保的案件中。神州细胞方面否认安佳因销售模式存在合规问题。前述裁判文书明确提及，神州细胞工程公司给予患者开药金额约4%的返点。药企以销售为目的给予患者返点涉嫌违反本条法规。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080904184194d86a02&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080904184194d86a02&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688520"],"gpt_icon":0},{"id":"2557514606","title":"生物制品公司财务总监PK：百万年薪以上占比41% 神州细胞马洁年薪143万行业第三","url":"https://stock-news.laohu8.com/highlight/detail?id=2557514606","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557514606?lang=zh_cn&edition=full","pubTime":"2025-08-08 11:33","pubTimestamp":1754623980,"startTime":"0","endTime":"0","summary":" 作为上市公司核心管理层关键成员，财务总监CFO的地位与作用至关重要。新浪财经《2024年度A股CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平均年薪为81.48万元。 分行业来看，统计数据显示，剔除2024年时任CFO已离任的公司后，A股共有24家上市生物制品公司，其聘任总体情况如下。其中，目前仍任职的最年轻的上市公司CFO年龄34岁，为智翔金泰-U的刘力文。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2025-08-08/doc-infkfuvz9163116.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688520","BK4218","PK","BK0239","BK4181"],"gpt_icon":0},{"id":"2557111135","title":"生物制品公司财务总监PK：50岁以上CFO占比为38% 智翔金泰刘力文为业内最年轻CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2557111135","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557111135?lang=zh_cn&edition=full","pubTime":"2025-08-08 11:31","pubTimestamp":1754623903,"startTime":"0","endTime":"0","summary":"新浪财经《2024年度A股CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平均年薪为81.48万元。从CFO的年龄分布来看，40岁-50岁CFO是市场的中坚力量，占比共计达到54%；50岁以上的CFO占比为38%；40岁及以下CFO占比为8%。其中，目前仍任职的最年轻的上市公司CFO年龄34岁，为智翔金泰-U的刘力文。从薪酬变动幅度看，2024年君实生物-U的许宝红薪酬降幅最大，同比降幅达24.66%；智翔金泰-U的刘力文薪酬增幅最大，同比涨幅达35.91%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808113149973af027&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808113149973af027&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688520","688278","688443","BK0239","688180","BK0216","688293"],"gpt_icon":0},{"id":"2557937530","title":"神州细胞今日主力净流出1.2亿 短期波动后看业绩兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2557937530","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557937530?lang=zh_cn&edition=full","pubTime":"2025-08-07 15:53","pubTimestamp":1754553214,"startTime":"0","endTime":"0","summary":"神州细胞今日主力资金净流出1.2亿元，上一交易日主力净流入1986.5万元。资金面与市场情绪共振引发短期波动近期神州细胞主力资金呈现多空博弈，政策红利与估值修正形成双向拉锯。截至8月5日，公司动态市盈率超300倍，显著高于行业均值，年内累计涨幅达93.62%，部分资金选择兑现收益，加剧了短期波动。随着业绩兑现能力成为估值锚点，商业化进程将主导长期走势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807163039a6d854e8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807163039a6d854e8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688520"],"gpt_icon":0},{"id":"2556338991","title":"生物类似药集采启动，国内企业将迎接“价格战”","url":"https://stock-news.laohu8.com/highlight/detail?id=2556338991","media":"健识局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556338991?lang=zh_cn&edition=full","pubTime":"2025-08-04 23:24","pubTimestamp":1754321076,"startTime":"0","endTime":"0","summary":"今年1月，安徽省医保局年度工作安排中提到了生物药集采，明确表示“将牵头全国生物药品联盟集采”。2019年百奥泰和博锐生物的生物类似药相继上市后，国产阿达木单抗的年费降至3万元以下。在此之前，复宏汉霖曾公开表示，正在积极应对生物类似药集采可能带来的冲击，并通过生物类似药的“出海”来应对市场挑战。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804232945a474ba81&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804232945a474ba81&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","BK0239","LU1655091616.SGD","01801","LU2495084118.USD","BK0012","02696","06955","600276","LU2580892789.USD","LU1997244956.HKD","LU2580892862.HKD","LU0405327494.USD","688520","LU1969619763.USD","688062","LU2148510915.USD","BK0196","688177","LU2488822045.USD","BK0188","LU1997245177.USD","LU1064130708.USD","BK0183","LU1997245094.SGD","LU2328871848.SGD","LU1064131003.USD","LU1328615791.USD","LU0405327148.USD","BK0060","BK0028"],"gpt_icon":0},{"id":"2556874228","title":"新冠药物概念盘中跳水，尖峰集团跌0.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2556874228","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556874228?lang=zh_cn&edition=full","pubTime":"2025-08-04 09:36","pubTimestamp":1754271410,"startTime":"0","endTime":"0","summary":"08月04日，新冠药物概念盘中跳水，截至09点36分，新冠药物概念整体指数下跌2.04%，报801.080点。从个股上来看，该概念的成分股中，尖峰集团跌0.49%，神州细胞、博瑞医药、之江生物跌幅居前。从资金上来看，截止发稿，新冠药物概念主力净流入为-3.45亿，其中博瑞医药受到资金热捧，主力净流入3637.01万；拉长时间线来看，该板块近20日主力资金净流入-68.41亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804093650a4733c8f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804093650a4733c8f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688520","600668","BK0235","BK0239","BK0186","BK0188"],"gpt_icon":0},{"id":"2556879631","title":"生物制品行业点评报告-减重赛道全球前沿进展跟踪(一)：AMYLIN布局正当时","url":"https://stock-news.laohu8.com/highlight/detail?id=2556879631","media":"开源证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556879631?lang=zh_cn&edition=full","pubTime":"2025-08-04 00:00","pubTimestamp":1754236800,"startTime":"0","endTime":"0","summary":"近期重磅BD 交易总结艾伯维和罗氏先后在2025 年一季度花重金布局amylin 分子。艾伯维将支付首付款3.5 亿美金，里程碑高达18.75 亿美金，以及销售分成。高质量减重方面，临床前DIO 大鼠数据显示Eloralintide 减少的体重最高达91%为脂肪。而目前GLP-1 类药物减重中约20%-40%为瘦体重。此外，礼来在ADA 大会上表示未来不排除eloralintide 开发月度制剂的可能性。Metsera 公司明确MET-223i 将定位为月度制剂。值得指出的是，Structure 和众生药业以小分子形式切入了amylin 赛道。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804093615a4733c3b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804093615a4733c3b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688336","603392","688520","688137","600161","688105","603087","688687","BK0239","688163","688319","688293","688177","688488","603590","688166","688278","688443","688670","688276","688739","600867","600211","600739"],"gpt_icon":0},{"id":"2556231308","title":"华创医药投资观点&研究专题周周谈·第137期：CXO行业：新周期、新起点","url":"https://stock-news.laohu8.com/highlight/detail?id=2556231308","media":"华创证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556231308?lang=zh_cn&edition=full","pubTime":"2025-08-02 00:00","pubTimestamp":1754064000,"startTime":"0","endTime":"0","summary":"本周行情回顾本周，中信医药指数上涨2.73%，跑赢沪深300指数4.48个百分点，在中信30个一级行业中排名第2位。本周涨幅前十名股票为南新制药、利德曼、辰欣药业、奇正藏药、广生堂、共同药业、亚太药业、上海谊众、众生药业、奥翔药业。本周跌幅前十名股票为*ST苏吴、三诺生物、博拓生物、神州细胞、交大昂立、天益医疗、皓元医药、鹿得医疗、山外山、仁度生物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250802191142a4713390&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250802191142a4713390&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["399275","600200","603367","688091","600530","688131","688520","603229","BK0239","159377","688189","688410","688767"],"gpt_icon":0},{"id":"2556186947","title":"神州细胞股价下跌5.01% 因资金博弈加剧股价震荡","url":"https://stock-news.laohu8.com/highlight/detail?id=2556186947","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556186947?lang=zh_cn&edition=full","pubTime":"2025-08-01 13:00","pubTimestamp":1754024439,"startTime":"0","endTime":"0","summary":"神州细胞股价大幅下跌，最新价71.05元/股，跌幅达5.01%。资金博弈加剧股价震荡近期神州细胞资金流向主要源于资金面剧烈波动。截至7月30日，公司动态市盈率高达328倍，年内累计涨幅106%促使获利盘集中兑现，融资余额单日骤降4770万元显示杠杆资金加速离场。当前股价回落至71元附近，311倍动态市盈率隐含管线兑现预期，但需警惕临床进展不及预期或政策调整引发的估值重构风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250801130050a6cd024c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250801130050a6cd024c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688520","BK0239"],"gpt_icon":0},{"id":"2555049569","title":"神州细胞收盘下跌3.53%，滚动市盈率328.47倍，总市值333.47亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2555049569","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555049569?lang=zh_cn&edition=full","pubTime":"2025-07-30 19:56","pubTimestamp":1753876602,"startTime":"0","endTime":"0","summary":"7月30日，神州细胞今日收盘74.88元，下跌3.53%，滚动市盈率PE达到328.47倍，总市值333.47亿元。从行业市盈率排名来看，公司所处的生物制品行业市盈率平均82.15倍，行业中值45.19倍，神州细胞排名第73位。股东方面，截至2025年3月31日，神州细胞股东户数11178户，较上次增加869户，户均持股市值35.28万元，户均持股数量2.76万股。2024年初，公司首次荣获北京市药监局“2023年度不良反应监测工作表现突出单位”称号。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/30195652093416.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","688520"],"gpt_icon":0},{"id":"2555085642","title":"单抗概念盘中拉升，苑东生物涨7.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555085642","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555085642?lang=zh_cn&edition=full","pubTime":"2025-07-29 10:14","pubTimestamp":1753755299,"startTime":"0","endTime":"0","summary":"07月29日，单抗概念盘中拉升，截至10点14分，单抗概念整体指数上涨1.10%，报2719.470点。从个股上来看，该概念的成分股中，苑东生物涨7.44%，迈威生物-U涨幅超过5%。从资金上来看，截止发稿，单抗概念概念主力净流入为-2.61亿，其中神州细胞受到资金热捧，主力净流入3545.89万；拉长时间线来看，该板块近20日主力资金净流入-5.13亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729101459a6c6dea6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729101459a6c6dea6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688062","688513","688520"],"gpt_icon":0},{"id":"2554716357","title":"华创医药投资观点&研究专题周周谈·第136期：高血压创新药是一笔好生意吗？","url":"https://stock-news.laohu8.com/highlight/detail?id=2554716357","media":"华创证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554716357?lang=zh_cn&edition=full","pubTime":"2025-07-26 00:00","pubTimestamp":1753459200,"startTime":"0","endTime":"0","summary":"本周行情回顾本周，中信医药指数上涨1.97%，跑赢沪深300指数0.28个百分点，在中信30个一级行业中排名第19位。本周涨幅前十名股票为海特生物、振东制药、塞力医疗、辰欣药业、仁度生物、康芝药业、易明医药、苑东生物、康泰医学、迈普医学。本周跌幅前十名股票*ST苏吴、永安药业、力生制药、首药控股-U、泽璟制药-U、科兴制药、信立泰、上海谊众、浙江震元、神州细胞。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726164141a4647f7b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726164141a4647f7b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159377","688520","688197","600200","603367","603716","688136","BK0239","688091","688193","688266","688513","399275","159992"],"gpt_icon":0},{"id":"2552174242","title":"生物制品行业盘中拉升，科兴制药涨8.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2552174242","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552174242?lang=zh_cn&edition=full","pubTime":"2025-07-17 10:01","pubTimestamp":1752717679,"startTime":"0","endTime":"0","summary":"07月17日，生物制品行业盘中拉升，截至10点01分，生物制品行业整体指数上涨1.00%，报6509.740点。从个股上来看，该行业的成分股中，科兴制药涨8.38%，神州细胞、智翔金泰-U2只股涨幅超过5%。从资金上来看，截止发稿，生物制品行业主力净流入为-4252.64万，其中神州细胞受到资金热捧，主力净流入6285.20万；拉长时间线来看，该板块近20日主力资金净流入-25.70亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071710011997a9217f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"4e7834c15c47c74e9bfd4d734ca81974","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071710011997a9217f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688136","688520"],"gpt_icon":0},{"id":"2552742731","title":"神州细胞涨5.05% 政策利好与机构资金流入推动股价上行","url":"https://stock-news.laohu8.com/highlight/detail?id=2552742731","media":"智选洞察","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552742731?lang=zh_cn&edition=full","pubTime":"2025-07-17 09:43","pubTimestamp":1752716632,"startTime":"0","endTime":"0","summary":"神州细胞股价今日大幅上涨，截至09点43分，最新价为77.95元/股，涨幅达5.05%。政策博弈与估值兑现共振近期神州细胞股价波动受多重短期因素影响。7月1日国家医保局创新药支持政策落地后，生物制品板块单日上涨1.67%，机构资金连续三日净流入超4700万元。但随后公司股东减持185.79万股，叠加创业板指波动超1%，引发单日股价回调2.77%。创新管线与商业化验证并重长期来看，神州细胞的核心竞争力取决于产品管线的研发进展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717094354a44fcd8f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717094354a44fcd8f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688520"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1757473047820,"stockEarnings":[{"period":"1week","weight":-0.0535},{"period":"1month","weight":-0.0817},{"period":"3month","weight":0.3009},{"period":"6month","weight":0.5727},{"period":"1year","weight":0.8913},{"period":"ytd","weight":0.6804}],"compareEarnings":[{"period":"1week","weight":-0.0132},{"period":"1month","weight":0.0474},{"period":"3month","weight":0.119},{"period":"6month","weight":0.1336},{"period":"1year","weight":0.3913},{"period":"ytd","weight":0.1359}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京神州细胞生物技术集团股份公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"9754人(较上一季度减少12.74%)","perCapita":"45656股","listingDate":"2020-06-22","address":"北京市大兴区北京经济技术开发区科创七街31号院5号楼307","registeredCapital":"44533万元","survey":" 北京神州细胞生物技术集团股份公司的主营业务是恶性肿瘤、自身免疫性疾病、感染性疾病和遗传病等多个治疗和预防领域的生物药产品研发和产业化。公司的主要产品是SCT800（安佳因）、SCT400（安平希）、SCT630（安佳润）、SCT510（安贝珠）、SCT-I10A（安佑平）、SCT1000SCT650C、SCTC21C、SCTB35、SCTB14、SCTB41、SCTV02、SCTV04C、SCT520FF、SCTT11、SCTB39-1、SCTB39G、SCT640C。","listedPrice":25.64},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.9","shortVersion":"4.34.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"神州细胞(688520)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供神州细胞(688520)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"神州细胞,688520,神州细胞股票,神州细胞股票老虎,神州细胞股票老虎国际,神州细胞行情,神州细胞股票行情,神州细胞股价,神州细胞股市,神州细胞股票价格,神州细胞股票交易,神州细胞股票购买,神州细胞股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"神州细胞(688520)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供神州细胞(688520)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}